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X-ray structure of hOX1R, in the form of
two cocrystal structures: (i) hOX1R bound
to suvorexant and (ii) hOX1R bound to the
hOX1R-selective compound SB-674042.
By combining the structural information
with computational, functional and radio-
ligand binding studies, Yin et al.5 provide
unprecedented molecular insight into the
ligand recognition and subtype selectivity of
these orexinergic antagonists.
The hOX1R structure reveals an N-terminal 
helix that is folded over the top of the ligand-
binding site of the receptor (Fig. 1) and appears 
to be critically involved in recruiting and bind-
ing the orexin peptide for receptor activation5. 
This N-terminal helix is not visible in the 
previously published hOX2R crystal struc-
ture, but sequence conservation suggests that 
both subtypes possess this structural motif. 
Similarly to the hOX2R structure, suvorexant 
neurons7. Orexin-receptor-knockout mice 
show increased sleepiness with shortened but 
intact waking bouts8, and studies have reported 
a 90% loss in orexinergic neurons in human 
narcolepsy 9. Chemogenetic approaches have 
shown that complementation of orexin- 
receptor loss improves narcoleptic symp-
toms10, and excitation or suppression of orexin 
neurons increases or decreases wakefulness in 
mice11, thus further highlighting the essential 
role of orexin-receptor signaling in maintain-
ing normal sleep patterns. Because an esti-
mated ~50% of adults in the United States 
suffer from symptoms of insomnia at least 
few nights a week12, a better understanding 
of the molecular basis of sleep homeostasis 
through hOX1R and hOX2R is of high thera-
peutic relevance.
Having previously determined the hOX2R 
structure13, Yin et al.5 now present the first 
Wakefulness in humans is mediated by acti-
vation of two orexinergic peptide receptors in 
the CNS, termed hOX1R and hOX2R1, which 
appear to ‘kick-start’ other neurotransmit-
ter systems required for alertness2 and goal- 
oriented behavior3. Not surprisingly, both 
orexin receptors are major targets for drug dis-
covery to treat insomnia and other disorders of 
wakefulness4. In this issue, Yin et al.5 report the 
structure of hOX1R bound to the anti-insomnia 
drug suvorexant (Merck’s Belsomra, the first 
US Food and Drug Administration–approved 
drug that targets both hOX1R and hOX2R). 
The authors also report the structure of hOX1R 
in complex with the hOX1R-selective ligand 
SB-647042; this structure, in combination with 
computational and functional studies, reveals 
the molecular mechanisms underlying orexin-
receptor subtype selectivity5.
hOX1R and hOX2R are G protein–coupled 
receptors activated by two distinct peptides, 
orexin-A and orexin-B1,6, in the lateral hypo-
thalamus, where they mediate the balance 
between wake- and sleep-promoting neuronal 
systems7. Activation of hOX1R and hOX2R 
promotes wakefulness, arousal and motiva-
tion via excitatory effects on many other neu-
rotransmitter systems including serotonergic, 
dopaminergic, noradrenergic, and histaminergic 
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Figure 1  Crystal structures of the human orexin receptor 1 (hOX1R, PDB 4ZJ8)5 and human orexin 
receptor 2 (hOX2R, PDB 4S0V)13 bound to the anti-insomnia drug suvorexant. Seven transmembrane 
bundles of hOX1R (blue) and hOX2R (orange) are shown with suvorexant (yellow) bound to the 
orthosteric site of the receptors. Insets show views of the orthosteric receptor sites from the extracellular 

































facilitate the generation of new chemical 
matter, providing a promising structural foun-
dation for new orexinergic therapeutics for a 
variety of pathological conditions.
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challenging to develop suitable chemi-
cal tools to study the distinct roles of each 
receptor in human physiology. Despite their 
restriction to the lateral hypothalamus, the 
orexin system projects to and receives inputs 
from several areas of the brain that medi-
ate motivation and anxiety2,7, including 
the limbic system and amygdala. It is thus 
conceivable that some projections may be 
governed by both orexin receptors, whereas 
others may be controlled by a single receptor 
subtype. Consequently, the development of 
orexin-receptor ligands with increased sub-
type selectivity may not only facilitate the 
study of distinct orexinergic pathways but 
also provide a path toward therapeutic 
intervention in conditions associated with 
a specific subtype. In fact, the hOX2R-se-
lective antagonist LSN2424100 shows anti-
depressant effects in rodents, whereas the 
hOX1R selective antagonists SB334867 and 
ACT-335827 appear to reduce fear and 
compulsive behaviors14–16.
These studies highlight the therapeutic 
promise of orexin-targeted drugs beyond 
their application in sleep disorders and, impor-
tantly, underscore the distinct roles of hOX1R 
and hOX2R in human physiology. Given the 
recent advances in structure-based virtual 
ligand screening17 and rational drug design18, 
the molecular insights into orexin-receptor 
function presented by Yin et al.5 should greatly 
displays a horseshoe-like conformation in the 
binding pockets of both receptors (Fig. 1), 
although clear differences in the orientation 
of the compound are evident between receptor 
subtypes.
The hOX1R-selective SB-674042 com-
pound reveals a conformation nearly iden-
tical to that of suvorexant, despite their 
completely different chemotypes (Fig. 2). 
From a drug-optimization perspective, it is 
interesting to note that the ligand–receptor 
contacts are predominantly hydrophobic, 
although both ligands contain numerous 
polar sites capable of forming of hydrogen 
bonds. To investigate ligand selectivity at 
the orexin receptors, the authors performed 
docking experiments of the hOX1R-selective 
SB-674042 compound into the binding site 
of the hOX2R structure and identified likely 
unfavorable contacts with two threonine resi-
dues. Indeed, the authors elegantly showed 
that mutating those threonines to the corre-
sponding hOX1R residues markedly increases 
the affinity of the hOX1R-selective compound 
but does not affect the binding of nonselec-
tive compounds.
Elucidating the molecular mechanisms 
of subtype selectivity at these important 
therapeutic targets represents a considerable 
advance, given the high sequence homol-
ogy and similar pharmacology of hOX1R 
and hOX2R. These similarities have made it 
Figure 2  Comparison of the orthosteric binding sites of hOX1R and hOX2R. Orthosteric binding sites are shown from the extracellular space. Extracellular 
residues have been removed for clarity. (a,b) Crystal structures of hOX1R (blue) with bound suvorexant (yellow) (a) and SB-674042 (magenta) (b).  
(c) hOX1R-selective ligand SB-674042 docked into the binding site of the hOX2R crystal structure (orange). hOX1R-receptor residues A1273.33 and S1032.61
(superscripts indicate Ballesteros-Weinstein numbering), which are responsible for binding the selective ligand SB-674042, are shown in green.
hOX2R-receptor residues T1353.33 and T1112.61, which impair high-affinity binding of the hOX1R-selective ligand SB-674042 to hOX2R, as identified by 


























a b chOX1R−suvorexant hOX1R−SB-674042
